fashion -WSS

fashion

author：fashion 2025-09-28 00:53:20 - browse：7

Courtesy Guardant Health

An independent panel of advisers to the Food and Drug Administration recommended the agency approve Guardant Health’s blood-based colon cancer detection test. If the agency follows the recommendation, it will clear an early hurdle for the test’s broader adoption.

The expert panel spent hours listening to presentations from Guardant, the FDA, and members of the public before voting on the screening test, called Shield. The panel’s nine voting members then voted on whether the test was safe, effective, and whether its benefits outweigh its risks, with eight, six, and seven panelists endorsing those views, respectively.

FDA approval is a requirement for winning coverage from the Centers for Medicare and Medicaid Services, which could be the difference between Guardant’s test becoming widespread — or irrelevant. In 2021, CMS denied coverage for Epi proColon, a different blood-based colon cancer test approved by the FDA. Soon after, the test’s maker, Epigenomics, announced that it would stop actively marketing the test, and last year the company announced a restructuring that included layoffs.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

WSS

Synthetic human embryos? Researchers say term is overblown

Illumina to lay off 10% of research and development team

Eating disorder hotline's move to chatbot carried cost for volunteers

GOP hopefuls to address prominent, controversial group questioning what's taught in schools

Medical experts exlpore how to eliminate bias in clinical algorithms

White House touts steps to stem shortages of cancer treatments

entertainment

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Hepatitis C has a cure — but many Americans still lack access to it

Telehealth for opioid use disorder is lifesaving

Bright Health sells Medicare Advantage business to Molina

Food makers tried to stack nutrition panel with preferred experts

Sports medicine is finally prioritizing gender equality

Illumina to lay off 10% of research and development team

Virginia high school admissions case could be legal follow

What to make of Biden’s latest efforts on cancer research

United colonoscopy coverage change 'may cost lives,' doctors say

Regeneron agrees to White House price limits on anti

focus

White House touts steps to stem shortages of cancer treatments

Diverse clinical trials: Why aren’t we there yet?

Prince Harry seeks over $550,000 in phone hacking lawsuit against British tabloid publisher

IRA could hurt research into orphan drugs for rare diseases

Private equity could exacerbate cardiology's overuse problem, experts fear

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

hotspot

leisure time

Wikipedia

knowledge